2 Information about nivolumab

Marketing authorisation indication

2.1 Nivolumab (Opdivo, Bristol—Myers Squibb) as monotherapy is indicated for 'the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum‑based therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price is £439 per 40‑mg vial, £1,097 per 100‑mg vial and £2,633 per 240‑mg vial (excluding VAT; BNF online [accessed June 2021] and company submission). The company has a commercial access agreement. This makes nivolumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)